Related to this topic: Patient+ | Equipment | Books | Your Experience | Other resources | Glossaries
Print options:
Other options:
(what's this?)
PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Autosomal Dominant Cerebellar Ataxia
Most forms of cerebellar ataxia are acquired disorders but hereditary forms can be autosomal dominant, recessive or a few are X-linked. By and large the dominant forms are less severe than recessive ones. An OMIM search for autosomal dominant cerebellar ataxia yields a very large number of results.
Mapping of genes has shown a vast array of conditions.1 Only a few will be considered here.
The classification includes the following diseases:
- Autosomal dominant cerebellar ataxia type I, II and III
- Cerebellar ataxia, dominant pure
- Cerebello-olivary atrophy
- Olivo-ponto-cerebellar atrophy
- Pierre Marie cerebellar ataxia
- Spinocerebellar ataxia, types 1-8,10-19,21-22
Autosomal dominant spinocerebellar ataxias (ADCA) are clinically and genetically varied disorders2 characterised by a slow progression of ataxia of gait, stance and limbs, dysarthria with or without oculomotor dysfunction due to cerebellar degeneration. The degenerative process can be limited to the cerebellum (ADCA type III) or may also involve the retina (ADCA type II), optic nerve, ponto-medullary systems, basal ganglia, cerebral cortex, spinal tracts or peripheral nerves (ADCA type I). In the genetic classification, ADCAs are called spinocerebellar ataxias (SCAs) and numbered in the order SCA1 to SCA22. They may show the phenomenon of anticipation with earlier onset and more severe disease in successive generations.
Prevalence of ADCAs has been estimated as between 0.8 and 3.5 per 100,000. It has been reported from many countries around the world.
Onset is usually between ages 30 and 50, although early onset in childhood and later onset after age 60 have been reported.
As well as cerebellar features there may be dementia, seizures, impaired proprioception, movement disorders, and polymyoclonus.
Symptoms
The following features are generally typical although there is some variation between diseases:
- Developmental delay
- Episodes of altered level of consciousness or recurrent neurological symptoms
- Family history of similar symptoms in a close relative
- Neurological or developmental regression
- Multi-system involvement in addition to neurological disease
- Presence of a particular neurological sign
Signs
- Ataxia is the fundamental neurological sign. Ataxia is the inability to maintain normal posture and smoothness of movement. There is a broad-based gait, scanning dysarthria, explosive speech, intention tremor, dysdiadochokinesia, dysmetria, and abnormalities of eye movements.
- There may be movement disorders.
- The picture ranges from pure cerebellar dysfunction to mixed patterns of involvement with extrapyramidal, brainstem, and cerebral cortical involvement.
There are many other forms of cerebellar ataxia, both acquired and inherited. A relatively important one is sporadic Creutzfeldt-Jakob disease that can present with predominantly cerebellar signs.3 In most cases of hereditary disease there will be a family history but not necessarily. Of the autosomal dominant types, only the features of SCA1, 2 and 3 are mentioned here as they are the commonest:
Spinocerebellar ataxia (SCA-1)
It is due to a mutation on the number 6 chromosome.4
Spinocerebellar ataxia (SCA-2)
It is due to a mutation on the number 12 chromosome and it is also known as Wadia-Swami syndrome.5
- Onset between 2 and 65 years
- Ataxia, facial fasciculation, lid retraction, dementia, peripheral neuropathy. The prognosis varies considerably even within families.
Spinocerebellar ataxia (SCA-3)
It is also called Machado-Joseph disease and affects people of Portuguese-Azorean descent. Clinical picture is variable. It has been traced back over 100 years in a single family.6 It is due to a mutation on the number 14 chromosome.7
- Onset is after the fourth decade
- Ataxia, pyramidal and extrapyramidal signs, amyotrophy, facial and lingual fasciculations, ophthalmoplegia, and exophthalmos
- A late feature may be autonomic dysfunction too.8
- Only 40% die as a result of the disease.9
- MRI may show atrophy of the cerebellum and brainstem and sometimes cerebral atrophy.10
- EEG may show features of epilepsy.
- Electromyography may demonstrates continuous motor unit activity
- Genetic testing may be possible. All these diseases represent an abnormality of metabolism due to a defect on a chromosome.
Non-Drug
Physiotherapy can help the ataxia.
Drugs
- Anticonvulsants may be required. In some forms acetalozamide is useful.
- In Machado-Joseph disease fluoxetine 20mg daily has been shown to improve motor function.11
- Tandospirone, a 5HT1A agonist appears to be beneficial.12
- Physostigmine is not helpful.13
Prognosis is highly variable between the different types but improvement is unlikely. Comparatively little is understood of the molecular processes involved in these diseases and so there is little chance of significant interventions to improve prognosis in the near future.14 There may also be multiple pathways involved.
Genetic testing enables identification of the causative gene in 50 to 80% of cases of ADCA.15 Pre-symptomatic testing is available but not always wanted. It is usually requested for family planning purposes. SCA3 is similar to Huntington's chorea in that the onset is fairly late in life, there is no effective treatment and screening may produce much anxiety. Most has been done in Portugal where the incidence of SCA3 is high. The psychological impact of testing does not seem high.16
Document References
- Albin RL; Dominant ataxias and Friedreich ataxia: an update. Curr Opin Neurol. 2003 Aug;16(4):507-14.; Curr Opin Neurol. 2003 Aug;16(4):507-14. [abstract]
- Kremer HP, van de Warrenburg BP, Sinke RJ; [From gene to disease; autosomal dominant cerebellar ataxias] Ned Tijdschr Geneeskd. 2004 Mar 27;148(13):614-6.; Ned Tijdschr Geneeskd. 2004 Mar 27;148(13):614-6. [abstract]
- Cooper SA, Murray KL, Heath CA, et al; Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the United Kingdom.; J Neurol Neurosurg Psychiatry. 2006 Jul 11;. [abstract]
- OMIM; SCA1
- OMIM; SCA2
- Teive HA, Arruda WO; [The Drew family of Walworth: one century from the first evaluation until the final diagnosis, Machado-Joseph disease] Arq Neuropsiquiatr. 2004 Mar;62(1):177-80. Epub 2004 Apr 28.; Arq Neuropsiquiatr. 2004 Mar;62(1):177-80. Epub 2004 Apr 28. [abstract]
- OMIM; SCA3 Machado-Jospeh disease
- Yeh TH, Lu CS, Chou YH, et al; Autonomic dysfunction in Machado-Joseph disease. Arch Neurol. 2005 Apr;62(4):630-6.; Arch Neurol. 2005 Apr;62(4):630-6. [abstract]
- Lima M, Coutinho P, Abade A, et al; Causes of death in Machado-Joseph disease: a case-control study in the Azores (Portugal). Arch Neurol. 1998 Oct;55(10):1341-4.; Arch Neurol. 1998 Oct;55(10):1341-4. [abstract]
- Ormerod IE, Harding AE, Miller DH, et al; Magnetic resonance imaging in degenerative ataxic disorders.; J Neurol Neurosurg Psychiatry. 1994 Jan;57(1):51-7. [abstract]
- Monte TL, Rieder CR, Tort AB, et al; Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand. 2003 Mar;107(3):207-10.; Acta Neurol Scand. 2003 Mar;107(3):207-10. [abstract]
- Takei A, Hamada T, Yabe I, et al; Treatment of cerebellar ataxia with 5-HT1A agonist.; Cerebellum. 2005;4(3):211-5. [abstract]
- Wessel K, Langenberger K, Nitschke MF, et al; Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases. Arch Neurol. 1997 Apr;54(4):397-400.; Arch Neurol. 1997 Apr;54(4):397-400. [abstract]
- Duenas AM, Goold R, Giunti P; Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006 Jun;129(Pt 6):1357-70. Epub 2006 Apr 13.; Brain. 2006 Jun;129(Pt 6):1357-70. Epub 2006 Apr 13. [abstract]
- Goizet C, Lesca G, Durr A; Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias. Neurology. 2002 Nov 12;59(9):1330-6.; Neurology. 2002 Nov 12;59(9):1330-6. [abstract]
- Rolim L, Leite A, Ledo S, et al; Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I. Clin Genet. 2006 Apr;69(4):297-305.; Clin Genet. 2006 Apr;69(4):297-305. [abstract]
Internet and Further Reading
- Prassad A; Ataxia with identified genetic and biochemical defects. emedicine September 2005
- www.ataxia.org.uk; Cerebellar ataxia. A guide for the medical profession
- Ataxia UK; Guide for patients
DocID: 1836
Document Version: 20
DocRef: bgp823
Last Updated: 16 Oct 2006
Review Date: 15 Oct 2008
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicineMedical reference articles in PatientPlus related to this topic (^ top of page)
Cerebellar Ataxia
Cerebellar LesionsOther - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
A-Z of UK Guidelines
A-Z of Online Videos
Medline
Other good health sites
Medical equipment products related to this topic (^ top of page)

Books related to this topic (^ top of page)

Want to search some more? Use the Google Search box below to search our site.

Would you like to try our advanced on-line knowledge support system designed to provide professionals with relevant up to date information about recognition and management of disease or take the Mentor Challenge?
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
